INAMED Corp. and Genzyme Surgical Products Sign Distribution Agreement.
INAMED Corp. (OTC BB:IMDC) and Genzyme Surgical Products Friday announced an agreement under which INAMED International Corp., an INAMED Corp. business unit, will distribute Genzyme's Snowden Pencer plastic surgery product line in five Western European countries.
The agreement covers Holland, France, Spain, Germany and the United Kingdom. Genzyme Surgical Products will continue to distribute its plastic surgery product line throughout the remainder of Europe using its existing distribution system.
"This agreement will strengthen our position in the rapidly growing plastic surgery market by giving us access to an established, specialized sales force," said Michael Lacey, Genzyme's vice president of plastic surgery products. "Our customers will benefit by having INAMED's highly trained and well-regarded sales force providing them with Snowden Pencer products."
INAMED International Corp. President and Chief Executive Officer Ken Pearce commented: "We are extremely pleased to add the well-respected Snowden Pencer plastic surgery product line to our growing array of value-added products that we are able to offer to the aesthetic medical community.
"The complementary nature of this alliance is demonstrated by each company's focus on precision breast surgery. The Snowden Pencer Tebbetts(TM) breast instrument set was designed to be used in conjunction with our most advanced technology style 410 cohesive gel breast implant."
Inamed is a global surgical and medical device company engaged in the development, manufacturing and marketing of medical devices for the plastic and reconstructive, bariatric and general surgery markets. INAMED manufactures and markets a variety of implantable products for plastic surgery procedures under the McGhan brand name.
The McGhan brand is universally recognized as the technology and market-leading name in implants for breast surgery. INAMED is collaborating to develop an array of novel human-based, tissue-engineering products for aesthetic and certain reconstructive applications.
Genzyme Surgical Products, a business unit of Genzyme General, markets instruments and devices for plastic, cardiovascular and general surgery. Genzyme's Snowden Pencer brand instruments have earned a reputation for quality.
Genzyme is also a leader in the development of biomaterials for adhesion prevention and is working to establish Seprafilm(R) Bioresorbable Membrane as the standard of care in colorectal surgeries. In addition, Genzyme Surgical Products is developing gene and cell therapy products to treat cardiovascular disease.
Genzyme's releases are available at http://www.genzyme.com and on the company's fax-on-demand service at 800/436-1443 in the United States or 201/521-1080 elsewhere.
INAMED's releases are available at http://www.inamedcorp.com and http://www.mcghan.com.